oncology
GI Cancer

Promising results with dual blockade of PDL-1 and VEGF in unresectable HCC

Atezolizumab in combination with bevacizumab is a promising first-line treatment option for people with unresectable hepatocellular carcinoma, ESMO 2019 delegates have heard. Presenting the results of the Phase 1b GO30140 study as a late breaking abstract Dr Michael Lee, MD, of the University of North Carolina Lineberger Comprehensive Cancer Center in Chapel Hill, said the ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic